PHAT (Phathom Pharma) Net Profit

Phathom Pharmaceuticals (PHAT) relies on US R&D centers while outsourcing the production of gastrointestinal drugs to third-party contractors. This price action chart on GURU.Markets shows that profit stands at -0.10, with the company increasing its pricing power through innovation despite pharmacy discounts. The business is considered a defensive asset, as demand for therapy remains stable regardless of economic conditions.

PHAT (Phathom Corp) Net Profit history from 07/04/2022 to 10/30/2026

Comprehensive metric breakdowns and analytics for Phathom Pharmaceuticals, Inc. (PHAT)

- price and consensus price forecast:

Stock Quotes Phathom|PHAT - Analyst Consensus Forecast

- business market valuation indicators:

Market Capitalization Phathom|PHAT - Real Price to Acquire Entire Company

- book capitalization data:

Accounting Value of a Share Phathom Pharmaceuticals|PHAT - Book Capitalization|Market Value to Equity Ratio phathompharma.com|PHAT - Company Total Assets

- debt and solvency information:

- net income and valuation multiples indicators:

PHAT - Net Income

Basic company analysis:Phathom PHAT

Mass-produced product of phathompharma.com

Phathom Pharmaceuticals (PHAT) is scaling its gastrointestinal disease therapies through strategic partnerships with clinics and distributors. Analyzing the company's aggregate financial results, an investor can observe the net profit dynamics. This metric measures actual cash generation, filtering out market noise. The current value of -0.10 reflects the efficiency of the commercialization of new drugs. This trend allows for an objective assessment of the asset's fundamental stability within a portfolio.

Direct competitors